Diagnosis, assessment, and phenotyping of COPD: beyond FEV1

International Journal of COPD

Volumn 11, Issue , 2016, Pages 3-12

  Lange, Peter ^a,b   Halpin, David M ^c   O’donnell, Denis E ^d   Macnee, William ^e  

^a HVIDOVRE HOSPITAL   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c ROYAL DEVON AND EXETER HOSPITAL   (United Kingdom)

^d KINGSTON GENERAL HOSPITAL   (Canada)

^e UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

ACOS; Asthma; COPD; Diagnosis; Phenotype

Indexed keywords

ALPHA 1 ANTITRYPSIN DEFICIENCY; ASTHMA; ASTHMA-CHRONIC OBSTRUCTIVE PULMONARY DISEASE OVERLAP SYNDROME; BLOOD SAMPLING; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC PROCEDURE; DISEASE ACTIVITY; DISEASE ASSESSMENT; DISEASE SEVERITY; EVIDENCE BASED PRACTICE; EXERCISE TEST; FORCED EXPIRATORY VOLUME; HUMAN; INSPIRATORY CAPACITY; PATIENT IDENTIFICATION; PHENOTYPE; REVIEW; THORAX RADIOGRAPHY; VALIDATION STUDY; DIFFERENTIAL DIAGNOSIS; LUNG; LUNG FUNCTION TEST; PATHOPHYSIOLOGY; PREDICTIVE VALUE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; REPRODUCIBILITY;

ASTHMA; DIAGNOSIS, DIFFERENTIAL; FORCED EXPIRATORY VOLUME; HUMANS; LUNG; PHENOTYPE; PREDICTIVE VALUE OF TESTS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; REPRODUCIBILITY OF RESULTS; RESPIRATORY FUNCTION TESTS;

EID: 85016107906     PISSN: 11769106     EISSN: 11782005     Source Type: Journal    
DOI: 10.2147/COPD.S85976     Document Type: Review

References (79)

1. Han MK, Agusti A, Calverley PM, et al. Chronic obstructive pulmonary disease phenotypes: the future of COPD. Am J Respir Crit Care Med. 2010;182(5):598–604.
2. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease [updated 2015]. Available from: http://www.goldcopd. org/uploads/users/files/GOLD_Report_2015_Feb18.pdf. Accessed March 30, 2015.
3. van der Molen T, Miravitlles M, Kocks JW. COPD management: role of symptom assessment in routine clinical practice. Int J Chron Obstruct Pulmon Dis. 2013;8:461–471.
4. Arne M, Emtner M, Janson S, Wilde-Larsson B. COPD patients perspec-tives at the time of diagnosis: a qualitative study. Prim Care Respir J. 2007;16(4):215–221.
5. Mannino DM, Sonia BA, Vollmer WM. Chronic obstructive pulmonary disease in the older adult: what defines abnormal lung function? Thorax. 2007;62(3):237–241.
6. Price DB, Yawn BP, Jones RC. Improving the differential diagnosis of chronic obstructive pulmonary disease in primary care. Mayo Clin Proc. 2010;85(12):1122–1129.
7. Puente-Maestu L, Stringer WW. Hyperinflation and its management in COPD. Int J Chron Obstruct Pulmon Dis. 2006;1(4):381–400.
8. Deesomchok A, Webb KA, Forkert L, et al. Lung hyperinflation and its reversibility in patients with airway obstruction of varying severity. COPD. 2010;7(6):428–437.
9. Casanova C, Cote C, de Torres JP, et al. Inspiratory-to-total lung capacity ratio predicts mortality in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2005;171(6):591–597.
10. O’Donnell DE, Guenette JA, Maltais F, Webb KA. Decline of rest-ing inspiratory capacity in COPD: the impact on breathing pattern, dyspnea, and ventilatory capacity during exercise. Chest. 2012;141(3): 753–762.
11. Agusti A, Calverley PM, Celli B, et al. Characterisation of COPD heterogeneity in the ECLIPSE cohort. Respir Res. 2010;11:122.
12. Pinto-Plata VM, Cote C, Cabral H, Taylor J, Celli BR. The 6-min walk distance: change over time and value as a predictor of survival in severe COPD. Eur Respir J. 2004;23(1):28–33.
13. Polkey MI, Spruit MA, Edwards LD, et al. Six-minute-walk test in chronic obstructive pulmonary disease: minimal clinically important dif-ference for death or hospitalization. Am J Respir Crit Care Med. 2013; 187(4):382–386.
14. Borel B, Provencher S, Saey D, Maltais F. Responsiveness of various exercise-testing protocols to therapeutic interventions in COPD. Pulm Med. 2013;2013:410748.
15. Tojo N, Ichioka M, Chida M, Miyazato I, Yoshizawa Y, Miyasaka N. Pulmonary exercise testing predicts prognosis in patients with chronic obstructive pulmonary disease. Intern Med. 2005;44(1):20–25.
16. Castaldi PJ, San Jose ER, Mendoza CS, et al. Distinct quantitative computed tomography emphysema patterns are associated with physiol-ogy and function in smokers. Am J Respir Crit Care Med. 2013;188(9): 1083–1090.
17. Coxson HO, Dirksen A, Edwards LD, et al. The presence and pro-gression of emphysema in COPD as determined by CT scanning and biomarker expression: a prospective analysis from the ECLIPSE study. Lancet Respir Med. 2013;1(2):129–136.
18. 1. Am J Respir Crit Care Med. 2014;190(2):135–144.
19. Pare PD, Nagano T, Coxson HO. Airway imaging in disease: gimmick or useful tool? J Appl Physiol (1985). 2012;113(4):636–646.
20. Vestbo J, Edwards LD, Scanlon PD, et al. Changes in forced expiratory volume in 1 second over time in COPD. N Engl J Med. 2011;365(13): 1184–1192.
21. Han MK, Kazerooni EA, Lynch DA, et al. Chronic obstructive pulmonary disease exacerbations in the COPDGene study: associated radiologic phenotypes. Radiology. 2011;261(1):274–282.
22. Mair G, Miller JJ, McAllister D, et al. Computed tomographic emphysema distribution: relationship to clinical features in a cohort of smokers. Eur Respir J. 2009;33(3):536–542.
23. Mair G, Maclay J, Miller JJ, et al. Airway dimensions in COPD: relation-ships with clinical variables. Respir Med. 2010;104(11):1683–1690.
24. Fishman A, Martinez F, Naunheim K, et al. A randomized trial com-paring lung-volume-reduction surgery with medical therapy for severe emphysema. N Engl J Med. 2003;348(21):2059–2073.
25. Williams MC, Murchison JT, Edwards LD, et al. Coronary artery calcification is increased in patients with COPD and associated with increased morbidity and mortality. Thorax. 2014;69(8): 718–723.
26. Hersh CP, Jacobson FL, Gill R, Silverman EK. Computed tomogra-phy phenotypes in severe, early-onset chronic obstructive pulmonary disease. COPD. 2007;4(4):331–337.
27. Vestbo J, Agusti A, Wouters EF, et al. Should we view chronic obstructive pulmonary disease differently after ECLIPSE? A clinical perspective from the study team. Am J Respir Crit Care Med. 2014;189(9):1022–1030.
28. Stoller JK, Aboussouan LS. A review of alpha1-antitrypsin deficiency. Am J Respir Crit Care Med. 2012;185(3):246–259.
29. Miravitlles M, Calle M, Soler-Cataluna JJ. Clinical phenotypes of COPD: identification, definition and implications for guidelines. Arch Bronconeumol. 2012;48(3):86–98.
30. Hurst JR, Vestbo J, Anzueto A, et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med. 2010;363: 1128–1138.
31. Albert RK, Connett J, Bailey WC, et al. Azithromycin for prevention of exacerbations of COPD. N Engl J Med. 2011;365(8):689–698.
32. Lee SJ, Lee SH, Kim YE, et al. Clinical features according to the frequency of acute exacerbation in COPD. Tuberc Respir Dis (Seoul). 2012;72(4):367–373.
33. Wedzicha JA, Brill SE, Allinson JP, Donaldson GC. Mechanisms and impact of the frequent exacerbator phenotype in chronic obstructive pulmonary disease. BMC Med. 2013;11:181.
34. O’Donnell DE, Gebke KB. Activity restriction in mild COPD: a challenging clinical problem. Int J Chron Obstruct Pulmon Dis. 2014;9:577–588.
35. Raghavan N, Ora J, Webb KA, O’Donnell DE. “Mild” chronic obstructive pulmonary disease – is there a case for earlier treatment? Annals of Respiratory Medicine. 2010;1(1):23–30.
36. Nishimura M, Makita H, Nagai K, et al. Annual change in pulmonary function and clinical phenotype in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2012;185(1):44–52.
37. Burgel PR, Paillasseur JL, Peene B, et al. Two distinct chronic obstructive pulmonary disease (COPD) phenotypes are associated with high risk of mortality. PLoS One. 2012;7(12):e51048.
38. Cavailles A, Brinchault-Rabin G, Dixmier A, et al. Comorbidities of COPD. Eur Respir Rev. 2013;22(130):454–475.
39. Agusti A, Edwards LD, Rennard SI, et al. Persistent systemic inflammation is associated with poor clinical outcomes in COPD: a novel phenotype. PLoS One. 2012;7(5):e37483.
40. Thomsen M, Dahl M, Lange P, Vestbo J, Nordestgaard BG. Inflammatory biomarkers and comorbidities in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2012;186(10):982–988.
41. Kim V, Davey A, Comellas AP, et al. Clinical and computed tomographic predictors of chronic bronchitis in COPD: a cross sectional analysis of the COPDGene study. Respir Res. 2014;15:52.
42. Izquierdo-Alonso JL, Rodriguez-Gonzalezmoro JM, de Lucas-Ramos P, et al. Prevalence and characteristics of three clinical phenotypes of chronic obstructive pulmonary disease (COPD). Respir Med. 2013; 107(5):724–731.
43. Fuschillo S, Martucci M, Donner CF, Balzano G. Airway bacterial colonization: the missing link between COPD and cardiovascular events? Respir Med. 2012;106(7):915–923.
44. Kiri VA, Soriano J, Visick G, Fabbri L. Recent trends in lung cancer and its association with COPD: an analysis using the UK GP Research Database. Prim Care Respir J. 2010;19(1):57–61.
45. Burger CD. Pulmonary hypertension in COPD: a review and consider-ation of the role of arterial vasodilators. COPD. 2009;6(2):137–144.
46. Hurdman J, Condliffe R, Elliot CA, et al. Pulmonary hypertension in COPD: results from the ASPIRE registry. Eur Respir J. 2013;41(6): 1292–1301.
47. Adir Y, Shachner R, Amir O, Humbert M. Severe pulmonary hypertension associated with emphysema: a new phenotype? Chest. 2012;142(6): 1654–1658.
48. Thomsen M, Nordestgaard BG, Vestbo J, Lange P. Characteristics and outcomes of chronic obstructive pulmonary disease in never smokers in Denmark: a prospective population study. Lancet Respir Med. 2013; 1(7):543–550.
49. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention [updated 2015 Apr]. Available from: www.ginasthma. org. Accessed May 1, 2015.
50. Vestbo J. Clinical assessment of COPD. In: Hanania NA, Sharafkhaneh A, editors. COPD: A Guide to Diagnosis and Clinical Management, Respiratory Medicine. Berlin, Germany: Springer, LLC; 2011.
51. Bateman ED, Hurd SS, Barnes PJ, et al. Global strategy for asthma management and prevention: GINA executive summary. Eur Respir J. 2008;31(1):143–178.
52. Barnes PJ. Immunology of asthma and chronic obstructive pulmonary disease. Nat Rev Immunol. 2008;8(3):183–192.
53. Bafadhel M, McCormick M, Saha S, et al. Profiling of sputum inflammatory mediators in asthma and chronic obstructive pulmonary disease. Respiration. 2012;83(1):36–44.
54. Shimizu K, Hasegawa M, Makita H, Nasuhara Y, Konno S, Nishimura M. Comparison of airway remodelling assessed by computed tomography in asthma and COPD. Respir Med. 2011;105(9):1275–1283.
55. James AL, Palmer LJ, Kicic E, et al. Decline in lung function in the Busselton Health Study: the effects of asthma and cigarette smoking. Am J Respir Crit Care Med. 2005;171(2):109–114.
56. Wang X, Mensinga TT, Schouten JP, Rijcken B, Weiss ST. Determi-nants of maximally attained level of pulmonary function. Am J Respir Crit Care Med. 2004;169(8):941–949.
57. Haldar P, Pavord ID, Shaw DE, et al. Cluster analysis and clinical asthma phenotypes. Am J Respir Crit Care Med. 2008;178(3):218–224.
58. Howrylak JA, Fuhlbrigge AL, Strunk RC, Zeiger RS, Weiss ST, Raby BA. Classification of childhood asthma phenotypes and long-term clinical responses to inhaled anti-inflammatory medications. J Allergy Clin Immunol. 2014;133(5):1289–1300.
59. Agusti A. The path to personalised medicine in COPD. Thorax. 2014; 69(9):857–864.
60. Nakawah MO, Hawkins C, Barbandi F. Asthma, chronic obstructive pulmonary disease (COPD), and the overlap syndrome. J Am Board Fam Med. 2013;26(4):470–477.
61. Zeki AA, Schivo M, Chan A, Albertson TE, Louie S. The asthma-COPD overlap syndrome: a common clinical problem in the elderly. J Allergy (Cairo). 2011;2011:861926.
62. Shaya FT, Dongyi D, Akazawa MO, et al. Burden of concomitant asthma and COPD in a Medicaid population. Chest. 2008;134(1):14–19.
63. Soriano JB, Davis KJ, Coleman B, Visick G, Mannino D, Pride NB. The proportional Venn diagram of obstructive lung disease: two approximations from the United States and the United Kingdom. Chest. 2003;124(2):474–481.
64. Meyers DA, Larj MJ, Lange L. Genetics of asthma and COPD. Similar results for different phenotypes. Chest. 2004;126(2 Suppl): 105S–110S.
65. Hershenson MB. Rhinovirus-induced exacerbations of asthma and COPD. Scientifica (Cairo). 2013;2013:405876.
66. Gaude GS. Pulmonary manifestations of gastroesophageal reflux dis-ease. Ann Thorac Med. 2009;4(3):115–123.
67. Boulet LP. Influence of comorbid conditions on asthma. Eur Respir J. 2009;33(4):897–906.
68. Chalmers GW, MacLeod KJ, Little SA, Thomson LJ, McSharry CP, Thomson NC. Influence of cigarette smoking on inhaled corticosteroid treatment in mild asthma. Thorax. 2002;57(3):226–230.
69. Colak Y, Afzal S, Nordestgaard BG, Lange P. Characteristics and prognosis of never smokers and smokers with asthma in the Copenhagen general population study: a prospective cohort study. Am J Respir Crit Care Med. 2015;192(2):172–181.
70. de Marco R, Pesce G, Marcon A, et al. The coexistence of asthma and chronic obstructive pulmonary disease (COPD): prevalence and risk factors in young, middle-aged and elderly people from the general population. PLoS One. 2013;8(5):e62985.
71. Kitaguchi Y, Komatsu Y, Fujimoto K, Hanaoka M, Kubo K. Sputum eosinophilia can predict responsiveness to inhaled corticosteroid treatment in patients with overlap syndrome of COPD and asthma. Int J Chron Obstruct Pulmon Dis. 2012;7:283–289.
72. Hardin M, Silverman EK, Barr RG, et al. The clinical features of the overlap between COPD and asthma. Respir Res. 2011;12:127.
73. Fu JJ, Gibson PG, Simpson JL, McDonald VM. Longitudinal changes in clinical outcomes in older patients with asthma, COPD and asthma-COPD overlap syndrome. Respiration. 2014;87(1):63–74.
74. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease [updated 2014 Jan]. Available from: http://www. goldcopd.com/guidelines-global-strategy-for-diagnosis-management. html. Accessed November 12, 2014.
75. Afshar K. Treatment based on phenotypic variants in chronic obstructive pulmonary disease. J Pulm Respir Med. 2013;3:e128.
76. Brightling CE, Monteiro W, Ward R, et al. Sputum eosinophilia and short-term response to prednisolone in chronic obstructive pulmonary disease: a randomised controlled trial. Lancet. 2000;356(9240):1480–1485.
77. Dummer JF, Epton MJ, Cowan JO, et al. Predicting corticosteroid response in chronic obstructive pulmonary disease using exhaled nitric oxide. Am J Respir Crit Care Med. 2009;180(9):846–852.
78. Agusti A, MacNee W. The COPD control panel: towards personalised medicine in COPD. Thorax. 2013;68(7):687–690.
79. O’Donnell DE, Laveneziana P. The clinical importance of dynamic lung hyperinflation in COPD. COPD. 2006;3(4):219–232.